Nanosystems Biology Cancer Center 2

NSBCC的组织是为了利用最先进的纳米技术科学与工程(加州理工学院)、最先进的系统生物学以及最先进的癌症生物学和临床肿瘤学(加州大学洛杉矶分校格芬医学院、琼森综合癌症中心和分子医学转化科学研究所)。 NSBCC的愿景是利用癌症生物学和临床肿瘤学的系统方法的测量和分析需求来推动新技术的科学和工程，然后通过我们与JCCC和IMED的合作伙伴关系将这些技术、计算工具和科学转移到扩大的临床研究和临床护理环境中。进一步的发展和影响是通过与营利性合作伙伴将技术商业化。此外，这些技术还可以通过获取生物信息和解决以前不可能解决的问题，开辟新的科学和临床机会。在过去的4年里，我们建立了一个由癌症生物学家、临床肿瘤学家、系统生物学家、物理学家和工程师组成的社区，他们共同努力，展示了体内分子成像诊断、体外诊断和纳米治疗从概念到临床的极快路径。新的IMED转译医学设施进一步扩大了我们从基础科学到患者护理的途径。拟议的NSBCC将在当前势头的基础上再接再厉，并将重点放在那些处于当今癌症生物学和临床肿瘤学中一些最具挑战性问题的核心的项目上。 主要的靶向癌症是胶质母细胞瘤和黑色素瘤，在资金周期的后期阶段应用于卵巢癌。中心主题是癌症的早期发现和靶向治疗的使能技术。对于所有的项目，都详细阐述了从桌面到床边的路径。与JCCC和IMED、几家生物技术公司的合作，以及其他一些NCI资助和基金会资助的项目(用于支持相关的临床试验和人体研究)利用了NSBCC的资源。 公共卫生相关性：CCNE开发的技术和生物信息为通过体外诊断和体内分子成像对黑色素瘤、胶质母细胞瘤和卵巢癌进行早期检测和信息诊断提供了一条途径。在拟议的项目中，将探索靶向治疗的直接应用，包括分子靶向治疗、过继T细胞免疫治疗和siRNA治疗。

The NSBCC is organized to take advantage of the state-of-the-art in the science & engineering of nanotechnology (Caltech), the state-of-the-art in the systems biology, and the state-of-the-art in cancer biology and clinical oncology (The UCLA Geffen School of Medicine, the Jonsson Comprehensive Cancer Center & the translational sciences Institute for Molecular Medicine. The NSBCC vision is to utilize the measurement and analysis needs of systems approaches to cancer biology and clinical oncology to drive the science and engineering of new technologies, and to then move those technologies, computational tools and science into an expanded clinical research and clinical care settings through our partnerships with JCCC and IMED. Further development and impact is through commercialization of technologies with for-profit partners. Those technologies can, in addition, open up new scientific and clinical opportunities through enabling access to biological information and solutions to problems that were previously not possible. Over the past 4 years we have built a community of cancer biologists, clinical oncologists, systems biologists, physical scientists and engineers who have worked together to demonstrate extremely rapid pathways from concept to clinic for in vivo molecular imaging diagnostics, in vitro diagnostics, and nanotherapeutics. The new IMED translation medicine facility further expands our avenue from basic science to patient care. The proposed NSBCC will build upon current momentum and will focus on projects that are at the heart of some of the most challenging problems in cancer biology and clinical oncology today. The major targeted cancers are glioblastoma and melanoma, with applications to ovarian cancer during the latter stages of the funding cycle. Central themes are early detection of cancer and enabling technologies for targeted therapies. For all projects, pathways from benchtop to bedside are elaborated. Partnerships with JCCC and IMED, several biotechnology companies, and a number of other NCI-funded and foundation funded programs (for supporting relevant clinical trials and human studies) leverage the NSBCC resources. Public Health Relevance: Technologies and biological information developed by this CCNE provides a pathway for the early detection and informative diagnosis of melanoma, glioblastoma, and ovarian cancers through in vitro diagnostics and in vivo molecular imaging. Direct applications to targeted therapies, including molecularly targeted therapies adoptive T cell immunotherapies, and siRNA therapies, are explored within the proposed Projects.